849634-86-2Relevant academic research and scientific papers
Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation
Trotter, B. Wesley,Nanda, Kausik K.,Kett, Nathan R.,Regan, Christopher P.,Lynch, Joseph J.,Stump, Gary L.,Kiss, Laszlo,Wang, Jixin,Spencer, Robert H.,Kane, Stefanie A.,White, Rebecca B.,Zhang, Rena,Anderson, Kenneth D.,Liverton, Nigel J.,McIntyre, Charles J.,Beshore, Douglas C.,Hartman, George D.,Dinsmore, Christopher J.
, p. 6954 - 6957 (2007/10/03)
Novel 3-cyanoisoquinoline Kv1.5 antagonists have been prepared and evaluated in in vitro and in vivo assays for inhibition of the Kv1.5 potassium channel and its associated cardiac potassium current, IKur. Structural modifications of isoquinoli
ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS
-
Page/Page column 40; 61, (2010/02/11)
The present invention relates to compounds of structural formula I: I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
